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Applying molecular immunohematology discoveries to daily transfusion practice
The discovery of the molecular basis of most red cell antigens, combined with advances 
in molecular testing, have paved the way for the use of genotyping to predict the red cell 
phenotype. Genotyping offers many advantages over serologic testing of recipients’ blood 
with the primary benefit being able to predict the blood group phenotype in situations that do 
not permit this serologically. 
Alloantibodies develop in approximately 2-4 percent of people after transfusion, with a 
higher rate (20-40 percent) among chronically transfused patients such as those with sickle 
cell anemia or thalassemia. Using hemagglutination to phenotype red blood cells from a 
person with alloantibodies can be complex and time consuming and the results can be difficult 
to interpret. In these cases, genotyping helps to predict the red cell antigen type and provides 
a more complete characterization of the blood type. 
The clinical benefits for the transfusion-dependent population are tangible: better matched 
blood decreases the risk of hemolytic transfusion reactions, especially delayed transfusion 
reactions to existing alloantibodies, and prevents new instances of alloimmunization. 
Additionally, the use of better matched blood can reduce transfusion requirements, decreasing 
the risk of transfusion-related acute lung injury and potential exposure to infectious diseases.
According to our experience, matching at DNA level can provide an added level of safety 
and efficacy for chronically transfused patients. Genotyping can also help to decrease costs, 
in both terms of time and money, associated with complex serologic workups and a higher 
number of transfusions.
In summary, molecular testing is a rapidly advancing field that offers tremendous 
potential in transfusion medicine and is proving to be a powerful tool to help serology, with 
the potential advantages of identifying rare blood and finding antigen matches for chronically 
transfused patients.
However, it is important to remember that, regardless of the test protocols used, genotyping 
can only predict a blood type. In rare situations a genotype determination will not correlate 
with the antigen expression on the red blood cell and appropriate assays are necessary to 
detect nucleotide changes that alter the predicted phenotype. Given the large number of known 
genetic events that silence or weaken the expression of antigens encoded by an allele, it will 
be a long time before all relevant nucleotide changes are revealed for all blood group systems 
in all ethnic groups. For these reasons, care must be taken when using molecular methods in 
antibody investigations as the serological problem may involve the inheritance of a null allele, 
a hybrid gene or a new variant. 
In this context, the analysis of blood group variants in a specific population is very 
important to predict a red cell phenotype using molecular methods. The more we learn about 
frequency and molecular background of such variants in different populations, the more 
accurate the genotype/phenotype results will be. For example, more work needs to be done 
to show that the molecular method used can recognize variants seen primarily in the African 
population. Two common examples are the GATA-promoter polymorphism, which silences 
the FY*B gene and two different GYPB alleles (GYPB*P2 and GYPB*NY) that silence the 
expression of the S antigen. 
The S-s- phenotype, with rare exception, is found only in persons of African descent and 
may be associated with the absence or weak expression of the high U antigen frequency. S-s- 
persons can develop anti-U, which is known to cause decreased survival of transfused antigen-
positive red blood cells. Therefore, it is very important to predict those phenotypes correctly. 
We have already shown in a specific blood donor population of African Brazilians that the 
S- and S-s-Uvar phenotypes can be associated with GYPB*P2 (73%) and GYPB*NY (27%) 
alleles (variant forms of GYPB)(1). In this issue, there is a paper on an admixed population of 
Minas Gerais showing that the S- and S-s-Uvar phenotypes are associated with the GYPB*P2 
allele characterized by a g>t mutation at +5 of the intron 5 donor splice site(2). Therefore, 
assays for routine analysis of GYPB in this population must include this single nucleotide 
polymorphism (SNP) in the final prediction of the phenotype in order to avoid false positive 
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results. This is a very interesting discovery that will help to apply 
blood group genotyping to standard practices. The available 
wealth of serologically defined variants has contributed to the 
rapid rate at which the genetic diversity of blood group genes has 
been revealed.
The pattern of genetic diversity of a specific genomic region 
depends both on the demographic history of populations and on 
locus specific evolutionary factors such as mutations, recombination 
and natural selection(3). The pattern of nucleotide diversity of GYPB 
is also informative about the role of S/s alleles in susceptibility to 
malaria infection, because it allows inferences about the action of 
natural selection driven by malaria during human evolution(4).
In addition, molecular immunohematology is providing us 
with the opportunity to implement a novel set of tools to personalize 
medicine and to adapt blood products to the clinical needs of patients.
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